Committee advances bill to clarify coverage for early-onset Alzheimer’s treatments, 7-0

Senator Richardson presented SB 950 on behalf of Senator Weber Pearson, saying the bill would ensure timely access to FDA-approved, medically necessary treatments for Californians with early-onset Alzheimer's disease. Richardson cited analysis from the California Health Benefits Review Program (CHBRP) estimating a premium impact of about three cents per member per month and noted state regulators find the near-term fiscal effect would be minor given currently limited treatment options.

Andrew Mendoza of the Alzheimer's Association, identified in testimony as a technical resource on the bill, told the committee he was available to answer questions but had no additional fiscal input. Committee staff advised the author that, while the bill was eligible for a vote that day, members had asked the author to consider an amendment adding a sunset clause to allow the Legislature to reassess costs should significant new treatments emerge.

Senator Cabaldon moved that SB 950 "do pass to the Senate floor." The clerk called the roll; members recorded aye votes and the committee announced a final tally of 7-0. The committee will return the bill to the floor; the author said she would continue working with the committee on technical amendments as the bill proceeds.

Why this matters: SB 950 would align private coverage with FDA-approved, medically necessary treatments for early-onset Alzheimer’s and was advanced by the committee on a unanimous vote; testimony emphasized both patient access and the expectation of limited near-term fiscal impact.